Why we need to achieve a full continuum of care in maternal and infant health

Why we need to achieve a full continuum of care in maternal and infant health

Through my ongoing collaboration with Medicaid and commercial health plans, as well as hospital NICU teams across the country, I am fortunate to witness the tremendous ongoing passion for improving maternal and infant health and health equity. However, passion alone will not propel us forward to the type of progress that women, their children, and … Read more

Vaping cessation programs are becoming critical for today’s workers

Vaping cessation programs are becoming critical for today’s workers

Vaping has become an increasing concern in the workplace, with almost 11 million adult Americans using vape products, according to the CDC. While many believe vaping is relatively harmless, more socially acceptable than smoking, and a useful tool to quit, nicotine is addictive and dangerous, no matter how it’s delivered. That’s why now’s the time … Read more

With overdoses skyrocketing, Congress must consider non-opioid alternatives to pain management

With overdoses skyrocketing, Congress must consider non-opioid alternatives to pain management

Drug overdose deaths in older adults have skyrocketed in recent years, jumping 147% over the last decade – the highest increase in any age group in the country. Among people 65 and older, men are twice as likely as women to suffer overdoses, and Black Americans are over 10% more likely than other minority groups. … Read more

Homeward secures $50M, partners with Priority Health for rural value-based care

Homeward secures M, partners with Priority Health for rural value-based care

When Dr. Jennifer Schneider, CEO of rural healthcare startup Homeward, was 12 years old, she was diagnosed with type 1 diabetes. But living in rural Minnesota, she did not see an endocrinologist for a long time. “It wasn’t until I went to medical school that I realized how scary and dangerous that was,” said Schneider, … Read more

FDA approval of AstraZeneca drug is first for a new group of breast cancer patients

FDA approval of AstraZeneca drug is first for a new group of breast cancer patients

A breast cancer drug from AstraZeneca and Daiichi Sankyo now has FDA approval to address a brand new category of the disease, a decision that enables the targeted therapy to reach a much broader patient population. The drug, Enhertu, was initially approved to address cancers characterized by the abundance of a protein called HER2. The … Read more

Most people with opioid use disorder don’t get meds for it, but these 3 changes could help

Most people with opioid use disorder don’t get meds for it, but these 3 changes could help

Medications that treat opioid use disorder (OUD) — such as methadone, buprenorphine and extended-release naltrexone — are life-saving drugs that have been tested to decrease opioid overdoses by more than half. However, 86.6% of people who have OUD are not receiving these medications, according to a study published Thursday in the International Journal of Drug … Read more

Weathering the good and the bad: Why good business practices work

Weathering the good and the bad: Why good business practices work

Wolves are fascinating creatures. They are intelligent, strong, and fierce. Many innovators are lone wolves. Many founders are as well. Sometimes the “lone wolf” moniker gets a bad rap, just as founders do. But the best of the lone wolf mythology is found in their independence, individuality, and a passion for a singular vision. These … Read more

3 reasons you should use NLP to make sense of SDOH

3 reasons you should use NLP to make sense of SDOH

It is widely recognized that social determinants of health (SDOH) can have a much greater impact than physical health in determining the overall well-being of individuals, especially in underserved communities. However, obtaining an understanding of how specific SDOH factors affect individuals is extremely difficult because SDOH data is not methodically collected by clinicians. Although SDOH … Read more

Amgen’s $3.7B ChemoCentryx acquisition adds a new piece to autoimmune strategy

Amgen’s .7B ChemoCentryx acquisition adds a new piece to autoimmune strategy

Amgen is shelling out nearly $4 billion to acquire ChemoCentryx, the latest in a string of M&A moves for the pharmaceutical giant and one that helps the company expand its approach to treating autoimmune diseases, and potentially also cancer. ChemoCentryx’s main asset is Tavneos, a treatment for ANCA-associated vasculitis, an autoimmune disease that damages organs, … Read more

Exploring strategies and innovations that deliver balance and wellbeing, expand access to health care, and dramatically improve health outcomes

Exploring strategies and innovations that deliver balance and wellbeing, expand access to health care, and dramatically improve health outcomes

Making the US healthcare system sustainable in the future is only possible if there is a recognition that many chronic diseases can be prevented, but it is a complex challenge. The strong correlation between chronic disease outcomes and mental health disorders underscores the disconnect of working to improve chronic disease outcomes without addressing mental health. … Read more